Group 1 - The core point of the news is that Insilico Medicine (03696) has entered into an exclusive licensing and co-development agreement with Shenzhen Hengtai Biotechnology Co., Ltd. for the ISM8969 project, aimed at accelerating the global development of a novel oral NLRP3 inhibitor for central nervous system diseases [1][2] - Under the agreement, Insilico will grant Hengtai the rights to research, develop, register, produce, and commercialize ISM8969 globally, with both parties holding 50% global rights to the project [1] - Insilico is set to receive up to $66 million (approximately HKD 514.8 million) in upfront and milestone payments, including an initial payment of $10 million (approximately HKD 78 million) expected within 30 days of the agreement's effective date [1] Group 2 - ISM8969 is positioned as a potential best-in-class NLRP3 inhibitor, discovered and optimized through Insilico's proprietary generative chemistry engine, Chemistry42 [2] - Preclinical studies have shown that ISM8969 exhibits excellent efficacy and safety, demonstrating significant anti-inflammatory activity across various disease models [2] - The compound has ideal blood-brain barrier (BBB) penetration capabilities, which may provide potential benefits for treating neuroinflammatory-related diseases [2]
英矽智能(03696)与衡泰生物达成超过5亿港元的全球战略合作共同开发新型血脑屏障穿透性NLRP3抑制剂